Nurix therapeutics presents data at the american association for cancer research (aacr) annual meeting highlighting activity of its btk targeted protein degraders, nx-2127 and nx-5948, against a broad range of btki resistance mutations

Oral presentation features structural disclosure and preclinical characterization of nx-2127, nurix's lead btk degrader for the treatment of b-cell malignancies

NRIX Ratings Summary

NRIX Quant Ranking